Competent/JJ
transcription/NN
initiation/NN
by/IN
RNA/NN
polymerase/NN
II/CD
in/IN
cell-free/JJ
extracts/NNS
from/IN
xeroderma/NN
pigmentosum/NN
groups/NNS
B/NN
and/CC
D/NN
in/IN
an/DT
optimized/VBN
RNA/NN
transcription/NN
assay/NN
./.

The/DT
human/JJ
autosomal/JJ
recessive/JJ
disease/NN
,/,
xeroderma/NN
pigmentosum/NN
(/(
XP/NN
)/)
,/,
can/MD
result/VB
from/IN
mutations/NNS
in/IN
any/DT
one/CD
of/IN
seven/CD
genes/NNS
,/,
designated/VBN
XPA/NN
through/IN
XPG/NN
./.
=====
Of/IN
these/DT
,/,
the/DT
XPB/NN
and/CC
XPD/NN
genes/NNS
encode/VBP
proteins/NNS
that/WDT
are/VBP
subunits/NNS
of/IN
a/DT
general/JJ
transcription/NN
factor/NN
,/,
TFIIH/NN
,/,
involved/VBN
in/IN
both/CC
nucleotide/NN
excision/NN
repair/NN
(/(
NER/NN
)/)
and/CC
initiation/NN
of/IN
mRNA/NN
transcription/NN
by/IN
RNA/NN
polymerase/NN
II/CD
./.
=====
In/IN
humans/NNS
,/,
mutation/NN
of/IN
the/DT
XPB/NN
or/CC
XPD/NN
gene/NN
impairs/VBZ
NER/NN
,/,
resulting/VBG
in/IN
hyper-sensitivity/NN
to/TO
sunlight/NN
and/CC
greatly/RB
increased/VBN
skin/NN
tumor/NN
formation/NN
./.
=====
However/RB
,/,
no/DT
transcription/NN
deficiency/NN
has/VBZ
been/VBN
demonstrated/VBN
in/IN
either/CC
XP-B/NN
or/CC
XP-D/NN
./.
=====
We/PRP
have/VBP
employed/VBN
an/DT
optimized/VBN
cell-free/JJ
RNA/NN
transcription/NN
assay/NN
to/TO
analyze/VB
transcription/NN
activity/NN
of/IN
XP-B/NN
and/CC
XP-D/NN
./.
=====
Although/IN
the/DT
growth/NN
rate/NN
was/VBD
normal/JJ
,/,
the/DT
XP-B/NN
and/CC
XP-D/NN
cells/NNS
contained/VBD
reduced/VBN
amounts/NNS
of/IN
TFIIH/NN
./.
=====
Extracts/NNS
prepared/VBN
from/IN
XP-B/NN
and/CC
XP-D/NN
lymphoblastoid/JJ
cells/NNS
exhibited/VBD
similar/JJ
transcription/NN
activity/NN
from/IN
the/DT
adenovirus/NN
major/JJ
late/JJ
promoter/NN
when/WRB
compared/VBN
to/TO
that/DT
in/IN
extracts/NNS
from/IN
normal/JJ
cells/NNS
./.
=====
Thus/RB
,/,
we/PRP
conclude/VBP
that/IN
the/DT
XP-B/NN
and/CC
XP-D/NN
lymphoblastoid/JJ
cells/NNS
do/VBP
not/RB
have/VB
impaired/JJ
RNA/NN
transcription/NN
activity/NN
./.
=====
We/PRP
consider/VBP
the/DT
possible/JJ
consequences/NNS
of/IN
the/DT
reduced/VBN
cellular/JJ
content/NN
of/IN
TFIIH/NN
for/IN
the/DT
clinical/JJ
symptoms/NNS
in/IN
XP-B/NN
or/CC
XP-D/NN
patients/NNS
,/,
and/CC
discuss/VBP
a/DT
'/``
conditional/JJ
phenotype/NN
'/''
that/WDT
may/MD
involve/VB
an/DT
impairment/NN
of/IN
cellular/JJ
function/NN
only/RB
under/IN
certain/JJ
growth/NN
conditions/NNS
./.